Evidence map›Paper›PMID 40104837›Full record

ArticleEngineering in life sciences2025

Recombinant Expression of a Ready-to-Use EGF Variant Equipped With a Single Conjugation Site for Click-Chemistry.

Melanie Krass, Meike Kolster, José Ignacio Valenzuela, Lena Moldenhauer, Marten Kagelmacher, Nicole Niesler, Alexander Weng, Marino Zerial, Gregor Nagel, Hendrik Fuchs

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Engineering in life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Melanie KrassInstitute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin Germany.
Meike KolsterInstitut für Pharmazie Freie Universität Berlin Berlin Germany.
José Ignacio ValenzuelaMax Planck Institute of Molecular Cell Biology and Genetics Dresden Germany.
Lena MoldenhauerInstitute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin Germany.
Marten KagelmacherInstitute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin Germany.
Nicole NieslerInstitute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin Germany.
Alexander WengInstitut für Pharmazie Freie Universität Berlin Berlin Germany.
Marino ZerialMax Planck Institute of Molecular Cell Biology and Genetics Dresden Germany.
Gregor NagelInstitute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin Germany.
Hendrik FuchsInstitute of Diagnostic Laboratory Medicine, Clinical Chemistry and Pathobiochemistry Charité-Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Berlin Germany.ORCID https://orcid.org/0000-0001-9153-9594

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The epidermal growth factor (EGF) receptor is commonly targeted in cancer therapy because it is overexpressed in many malignant cells. However, a general problem is to couple the targeting moieties and the drug molecules in a way that results in a homogeneous product. Here, we overcome this issue by engineering a variant of EGF with a single conjugation site for coupling virtually any payload. The recombinant EGF variant K-EGF

Indexed as

click‐chemistryepidermal growth factorligand variantsingle conjugation sitetargeted therapy

Identifiers

PMID40104837
PMCPMC11913717

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.